Similar articles

• Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.

  Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. Yamamoto S, et al. J Gastroenterol Hepatol. 2010 May;25(5):886-91. doi: 10.1111/j.1440-1746.2009.06206.x. J Gastroenterol Hepatol. 2010. PMID: 20546441
• [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].

  Ainsworth MA, Brynskov J. Ainsworth MA, et al. Ugeskr Laeger. 2007 Feb 26;169(9):789-91. Ugeskr Laeger. 2007. PMID: 17355841 Review. Danish.
• Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.

  Yamamoto-Furusho JK, Uzcanga LF. Yamamoto-Furusho JK, et al. Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882. Epub 2008 Nov 13. Dig Surg. 2008. PMID: 19005257
• Rescue with infliximab and surgical outcomes for refractory ulcerative colitis.

  Actis GC, Pellicano R, Pinna-Pintor M, Rizzetto M. Actis GC, et al. J Am Coll Surg. 2007 Oct;205(4):e3-4. doi: 10.1016/j.jamcollsurg.2007.06.319. J Am Coll Surg. 2007. PMID: 17903716 No abstract available.
• A review of infliximab use in ulcerative colitis.

  Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. Wilhelm SM, et al. Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Clin Ther. 2008. PMID: 18343261 Review.